IAG933 | TEAD inhibitor | CAS#2714434-21-4

MedKoo Cat#: 128344 | Name: IAG933

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IAG933 is a TEAD inhibitor.

Chemical Structure

IAG933

CAS#2714434-21-4

Theoretical Analysis

MedKoo Cat#: 128344

Name: IAG933

CAS#: 2714434-21-4

Chemical Formula: C27H26ClF2N3O4

Exact Mass: 529.1580

Molecular Weight: 529.97

Elemental Analysis: C, 61.19; H, 4.95; Cl, 6.69; F, 7.17; N, 7.93; O, 12.08

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

IAG933; IAG 933; IAG-933; YAP-TEAD-IN-3

IUPAC/Chemical Name

4-((2S,4R)-5-chloro-6-fluoro-2-phenyl-2-((S)-pyrrolidin-2-yl)-2,3-dihydrobenzofuran-4-yl)-5-fluoro-6-(2-hydroxyethoxy)-N-methylnicotinamide

InChi Key

HUVOYQMXUNTUAI-DCFHFQCYSA-N

InChi Code

InChI=1S/C27H26ClF2N3O4/c1-31-25(35)17-14-33-26(36-11-10-34)24(30)22(17)21-16-13-27(20-8-5-9-32-20,15-6-3-2-4-7-15)37-19(16)12-18(29)23(21)28/h2-4,6-7,12,14,20,32,34H,5,8-11,13H2,1H3,(H,31,35)/t20-,27-/m0/s1

SMILES Code

ClC(C(F)=CC1=C2C[C@](C3=CC=CC=C3)([C@@H]4CCCN4)O1)=[C@]2[C@@]5=C(C(NC)=O)C=NC(OCCO)=C5F

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 529.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chapeau EA, Sansregret L, Galli GG, Chène P, Wartmann M, Mourikis TP, Jaaks P, Baltschukat S, Barbosa IAM, Bauer D, Brachmann SM, Delaunay C, Estadieu C, Faris JE, Furet P, Harlfinger S, Hueber A, Jiménez Núñez E, Kodack DP, Mandon E, Martin T, Mesrouze Y, Romanet V, Scheufler C, Sellner H, Stamm C, Sterker D, Tordella L, Hofmann F, Soldermann N, Schmelzle T. Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo- dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024 Jul;5(7):1102-1120. doi: 10.1038/s43018-024-00754-9. Epub 2024 Apr 2. Erratum in: Nat Cancer. 2024 Jul;5(7):1130. doi: 10.1038/s43018-024-00797-y. PMID: 38565920; PMCID: PMC11286534. 2: Chapeau EA, Sansregret L, Galli GG, Chène P, Wartmann M, Mourikis TP, Jaaks P, Baltschukat S, Barbosa IAM, Bauer D, Brachmann SM, Delaunay C, Estadieu C, Faris JE, Furet P, Harlfinger S, Hueber A, Jiménez Núñez E, Kodack DP, Mandon E, Martin T, Mesrouze Y, Romanet V, Scheufler C, Sellner H, Stamm C, Sterker D, Tordella L, Hofmann F, Soldermann N, Schmelzle T. Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers. Nat Cancer. 2024 Jul;5(7):1130. doi: 10.1038/s43018-024-00797-y. Erratum for: Nat Cancer. 2024 Jul;5(7):1102-1120. doi: 10.1038/s43018-024-00754-9. PMID: 38886525; PMCID: PMC11286518. 3: Chène P. Direct Inhibition of the YAP : TEAD Interaction: An Unprecedented Drug Discovery Challenge. ChemMedChem. 2024 Oct 1;19(19):e202400361. doi: 10.1002/cmdc.202400361. Epub 2024 Jul 24. PMID: 38863297. 4: Zhao B, Pobbati AV, Rubin BP, Stauffer S. Leveraging Hot Spots of TEAD- Coregulator Interactions in the Design of Direct Small Molecule Protein-Protein Interaction Disruptors Targeting Hippo Pathway Signaling. Pharmaceuticals (Basel). 2023 Apr 13;16(4):583. doi: 10.3390/ph16040583. PMID: 37111340; PMCID: PMC10146773. 5: Roy ME, Elimam R, Zgheib A, Annabi B. A Role for the Hippo/YAP1 Pathway in the Regulation of In Vitro Vasculogenic Mimicry in Glioblastoma Cells. J Cell Mol Med. 2024 Dec;28(24):e70304. doi: 10.1111/jcmm.70304. PMID: 39718433; PMCID: PMC11667753.